Thematische Bibliographien / Small Cell Lung Cancer

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte
  6. Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Small Cell Lung Cancer“

Autor: Grafiati
Veröffentlicht am 4. Juni 2021
Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Small Cell Lung Cancer" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Small Cell Lung Cancer"

1

Greschuchna, D. "Surgical Treatment of Small Cell Lung Cancer." Journal of the Japanese Association for Chest Surgery 3, no. 2 (1989): 169. http://dx.doi.org/10.2995/jacsurg1987.3.2_169.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Skenduli, Ilir, and Perlat Kapisyzi. "Surgery for Non Small Cell Lung Cancer - A Systematic Review." International Journal of Science and Research (IJSR) 11, no. 5 (2022): 1551–56. http://dx.doi.org/10.21275/sr22518021202.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

_, _. "Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 6, no. 3 (2008): 294. http://dx.doi.org/10.6004/jnccn.2008.0025.

Der volle Inhalt der Quelle
Annotation:
Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment,
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Hellriegel, H. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-12.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Klaus-Peter, K. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-6-12.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Kammaev, K. A. "Non-small cell lung carcinoma. Clinical case." Filin’s Clinical endoscopy 66, no. 3 (2024): 62–65. http://dx.doi.org/10.31146/2415-7813-endo-66-3-62-65.

Der volle Inhalt der Quelle
Annotation:
In 2020, 2.2 million new cases of lung cancer were reported. The main form of lung cancer is non-small cell carcinoma (85%). Non-small cell lung cancer has 3 subtypes: adenocarcinoma, large cell and squamous cell carcinoma. Squamous cell lung cancer occurs in 20-40% of all lung cancers. Squamous cell lung cancer is associated with an unfavorable outcome. 5-year survival rate not exceeding 18%.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Kalemkerian, Gregory P., Wallace Akerley, Paul Bogner, et al. "Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 9, no. 10 (2011): 1086–113. http://dx.doi.org/10.6004/jnccn.2011.0092.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Kalemkerian, Gregory P., Wallace Akerley, Paul Bogner, et al. "Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 11, no. 1 (2013): 78–98. http://dx.doi.org/10.6004/jnccn.2013.0011.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Byrne, Bernadette. "Small cell lung cancer." Nursing Standard 8, no. 9 (1993): 23–28. http://dx.doi.org/10.7748/ns.8.9.23.s42.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Hinson, J. A., and M. C. Perry. "Small cell lung cancer." CA: A Cancer Journal for Clinicians 43, no. 4 (1993): 216–25. http://dx.doi.org/10.3322/canjclin.43.4.216.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Small Cell Lung Cancer"

1

Sarvi, Sana. "Small cell lung cancer and cancer stem cell-like cells." Thesis, University of Edinburgh, 2014. http://hdl.handle.net/1842/9542.

Der volle Inhalt der Quelle
Annotation:
Small cell lung cancer (SCLC) is a highly aggressive malignancy with extreme mortality and morbidity. Although initially chemo- and radio-sensitive, almost inevitable recurrence and resistance occurs. SCLC patients often present with metastases, making surgery not feasible. Current therapies, rationally designed on underlying pathogenesis, produce in vitro results, however, these have failed to translate into satisfactory clinical outcomes. Recently, research into cancer stem cells (CSCs) has gained momentum and form an attractive target for novel therapies. Based on this concept, CSCs are the
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Kapeleris, Joanna C. "Circulating tumour cells in non-small cell lung cancer." Thesis, Queensland University of Technology, 2022. https://eprints.qut.edu.au/228607/1/Joanna_Kapeleris_Thesis.pdf.

Der volle Inhalt der Quelle
Annotation:
Circulating tumour cells (CTCs) have the potential to transform the management of patients with non-small cell lung cancer (NSCLC). The applications of CTCs can identify clinically actionable targets to predict treatment response and to better understand metastasis. CTCs isolated using microfluidics can be used as prognostic indicators of NSCLC as well as characterizing for markers of immunotherapy (PD-L1), molecular targets (ALK, EGFR). Short term cultures were successfully expanded in 9/70 NSCLC patients and cultured for up to 3 months. Optimization of this novel CTC culture model provides o
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Wang, Wei. "Modulation of immune cell responses by small cell lung cancer cells." Thesis, King's College London (University of London), 2016. https://kclpure.kcl.ac.uk/portal/en/theses/modulation-of-immune-cell-responses-by-small-cell-lung-cancer-cells(7bdc85c2-acd8-4f13-9d2b-e2ce07d1567b).html.

Der volle Inhalt der Quelle
Annotation:
Small Cell Lung Cancer (SCLC) accounts for 15-20% of all lung cancers and kills at least one person every 2 hours in the UK. There is no effective treatment and overall 2-year survival is less than 5%. Patients with SCLC have poorly understood local and systemic immune defects. Previous studies have shown several important defects in cell-mediated immune responses in patients with SCLC. A better understanding of interactions between SCLC tumour cells and immune cells may lead to the development of novel therapeutic approaches. There is increasing recognition that immunological biomarkers may a
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Oosterhout, Anselmus Gerardus Maria van. "Small cell lung cancer and brain metastasis." Maastricht : Maastricht : Rijksuniversiteit Limburg ; University Library, Maastricht University [Host], 1995. http://arno.unimaas.nl/show.cgi?fid=6643.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Seute, Tatjana. "Neurologic complications in small cell lung cancer." Maastricht : Maastricht : Universiteit Maastricht ; University Library, Universiteit Maastricht [host], 2008. http://arno.unimaas.nl/show.cgi?fid=9520.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Macaulay, Valentine. "Growth regulation in small cell lung cancer." Thesis, Imperial College London, 1989. http://hdl.handle.net/10044/1/47547.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Sikkink, Stephen K. "Genetic pathology of non-small cell lung cancer." Thesis, University of Liverpool, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.250405.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Brena, Romulo Martin. "Aberrant DNA methylation in human non-small cell lung cancer." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1172083621.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Wong, Wing-sze, and 黃詠詩. "Fusion genes in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43781378.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Ng, Sheng Rong. "CRISPR-mediated interrogation of small cell lung cancer." Thesis, Massachusetts Institute of Technology, 2018. http://hdl.handle.net/1721.1/117782.

Der volle Inhalt der Quelle
Annotation:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2018.<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>Cataloged student-submitted from PDF version of thesis. Vita.<br>Includes bibliographical references.<br>Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung carcinoma that remains among the most lethal of solid tumor malignancies. Despite decades of research, treatment outcomes for SCLC remain very poor, highlighting the need for novel appr
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Small Cell Lung Cancer"

1

S, Seeber, ed. Small cell lung cancer. Springer-Verlag, 1985.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Seeber, Siegfried, ed. Small Cell Lung Cancer. Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-82372-5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

T, Carr David, and International Cancer Research Data Bank., eds. Non-small cell lung cancer. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Jerome, Seidenfeld, Blue Cross and Blue Shield Association. Technology Evaluation Center., and United States. Agency for Healthcare Research and Quality., eds. Management of small cell lung cancer. Agency for Healthcare Research and Quality, Public Health Service, U.S. Dept. of Health and Human Services, 2006.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Postmus, Pieter Edsge. New approaches in small cell lung cancer. [s.n.], 1985.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Carr, David T. Selected abstracts on small cell lung cancer. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1986.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Ramaswamy, Govindan, ed. Locally advanced non-small-cell lung cancer. CMP United Business Media, 2004.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

1935-, Skarin Arthur T., and Alexander Eben, eds. Multimodality treatment of lung cancer. M. Dekker, 2000.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

IASLC Workshop on Small Cell Lung Cancer (3rd 1989 Helsingør, Denmark). Management of small cell lung cancer: Third IASLC Workshop on Small Cell Lung Cancer, Elsinore, Denmark, 18-22 June, 1989. Edited by Hansen Heine Høi, Kristjansen Paul E. G, and International Association for the Study of Lung Cancer. Elsevier, 1989.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Benjamin, Movsas, Langer Corey J, and Goldberg Melvyn, eds. Controversies in lung cancer: A multidisciplinary approach. M. Dekker, 2001.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Small Cell Lung Cancer"

1

Ravenel, James G. "Small Cell Carcinoma." In Lung Cancer Imaging. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-60761-620-7_7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Munden, Reginald F., and Jeremy J. Erasmus. "Thoracic Imaging Techniques for Non-Small Cell and Small Cell Lung Cancer." In Lung Cancer. Springer New York, 2003. http://dx.doi.org/10.1007/0-387-22652-4_3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Hansen, Heine H. "Small Cell Lung Cancer Treatment." In Lung Cancer. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76031-0_20.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Hanrahan, Emer O., and Bonnie Glisson. "Small Cell Carcinoma of the Lung." In Lung Cancer. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-524-8_16.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Hann, Christine L. "Small Cell Lung Cancer: Biology Advances." In Lung Cancer. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-74028-3_9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Gomez, Daniel, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki. "Combinations of Radiation Therapy and Chemotherapy for Non-Small Cell and Small-Cell Lung Carcinoma." In Lung Cancer. John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch23.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Rathore, Ritesh, and Alan B. Weitberg. "Small-Cell Lung Cancer." In Cancer of the Lung. Humana Press, 2002. https://doi.org/10.1007/978-1-59259-093-3_12.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Rathore, Ritesh, and Alan B. Weitberg. "Small-Cell Lung Cancer." In Cancer of the Lung. Humana Press, 2002. https://doi.org/10.1007/978-1-59259-093-3_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Gadgeel, Shirish. "Small Cell Lung Cancer." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_6764-2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Gadgeel, Shirish. "Small Cell Lung Cancer." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-46875-3_6764.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Small Cell Lung Cancer"

1

Patel, Sagar S., Ramesh Natarajan, and Rebecca L. Heise. "Mechanotransduction of Primary Cilia in Lung Adenocarcinoma." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80435.

Der volle Inhalt der Quelle
Annotation:
Lung cancer causes more than 1 million deaths worldwide annually [1]. In a recent study by the American Cancer Society in 2011, more than 221,000 new cases of lung cancers were reported [2]. Out of these, the mortality rate was found in roughly 70% of the cases [2]. Lung cancer is divided into two major categories: small cell and non-small cell. In the United States, non-small cell lung cancer accounts for 85% of all lung cancers and is considered the most common type of lung cancer [2]. It is usually resistant to chemotherapy, therefore making it extremely difficult to treat [3]. Furthermore
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Gileva, M. S., E. G. Ufimceva, L. F. Gulyaeva, and V. V. Kozlov. "EX VIVO CHARACTERISTICS OF NON-SMALL CELL LUNG CANCER CELLS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-308.

Der volle Inhalt der Quelle
Annotation:
The search for molecular markers for the identification of adenocarcinoma and squamous cell lung cancer remains an urgent problem. In this work, for the first time, an ex vivo method was used to isolate cells from tissue samples of patients with non-small cell lung cancer. Potential markers of this histological tumor type were analyzed, and the cellular composition of the immune microenvironment was also assessed, including depending on the smoking status of patients.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Benammar, Sarra, Fatima Mraiche, Jensa Mariam Joseph, and Katerina Gorachinova. "Glucose and Transferrin Liganded PLGA Nanoparticles Internalization in Non-Small Lung Cancer Cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0227.

Der volle Inhalt der Quelle
Annotation:
Introduction: Recently, after a decade of confusing results, several studies pointed out that overexpression of GLUT1 (glucose transporter 1) is a biomarker of worse prognosis in NSCLC. Nonetheless, the presence of transferrin (Tf receptor), which is overexpressed in most cancer tissues and most lung cancers as well, in NSCLC is also an indicator of very poor prognosis. Therefore, these ligands can be used for active targeting of lung cancer cells and improved efficacy of internalization of cancer therapy using nanomedicines. Objectives: Having the background, the main goal of the project was
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Hider, Nabilah Hanani, Anis Salwa Binti Mohd Khairuddin, and Effariza Binti Hanafi. "VGG Classification Model for Lung Cancer Diagnosis." In International Technical Postgraduate Conference 2022. AIJR Publisher, 2022. http://dx.doi.org/10.21467/proceedings.141.9.

Der volle Inhalt der Quelle
Annotation:
Lung cancer is one of the most common cancers worldwide that leads to small survival rate. It is important to detect the presence of these harmful cells in human body at early stages to prevent it from worsening. The primary goal of this study is to propose an efficient lung cancer image classification model using deep learning method. The cancer image classification framework is proposed by using transfer learning with Convolutional Neural Network (CNN) to classify three categories of 5,100 cancer images namely lung adenocarcinoma, lung squamous cell carcinoma and benign lung tissues obtained
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Jabbour, E., P. Sidhom, and R. El-Bizri. "Small Cell Lung Cancer, Does It Cavitate." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7012.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Hamedi, Z., S. Kamboj, S. Kumar, R. A. Jiwani, and N. Sharma. "Transformation of Non-Small Cell Lung Cancer (NSCLC) to Small Cell Lung Cancer (SCLC), Mechanism of Treatment Resistance?" In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4871.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Hunting, John, Sarah Price, Logan Deyo, et al. "1188 Comparative differences of irAE between extensive stage small cell lung cancer and non-small cell lung cancer." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.1188.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Xing, Fuyong, and Lin Yang. "Robust cell segmentation for non-small cell lung cancer." In 2013 IEEE 10th International Symposium on Biomedical Imaging (ISBI 2013). IEEE, 2013. http://dx.doi.org/10.1109/isbi.2013.6556493.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Doerr, F., S. Stange, A. Gassa, et al. "It Is Worth Operating Small Cell Lung Cancer?" In 48th Annual Meeting German Society for Thoracic, Cardiac, and Vascular Surgery. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1678934.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Dias, Margarida, Raquel Marçoa, Rita Linhas, Sérgio Campainha, Sara Conde, and Ana Barroso. "Non-small cell lung cancer in never-smokers." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2796.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Small Cell Lung Cancer"

1

Freire, Mariana, Diana Martins, Maria Filomena Botelho, and Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.

Der volle Inhalt der Quelle
Annotation:
Review question / Objective: This systematic review aims to provide an overview of the immunotherapy resistance mechanisms and identify potential biomarkers associated with immunotherapy response in NSCLC, as well as examine new treatment options to overcome this hurdle. Condition being studied: Lung Cancer (LC) remains one of the leading cancers worldwide. In 2020, were globally estimated 2 206 771 new cases and 1 796 144 deaths, representing the uttermost frequent cause of cancer death. LC is classified histologically into small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC),
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Kang, Jing, Jun Zhang, Zongsheng Tian, Ye Xu, Jiangbi Li, and Mingxina Li. The efficacy and safety of immune-checkpoint inhibitor plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0156.

Der volle Inhalt der Quelle
Annotation:
Review question / Objective: Population: histologically confirmed advanced NSCLC patients; Intervention: received immune-checkpoint inhibitor plus chemotherapy; Comparison:received chemotherapy; Outcome: reported OS, PFS, ORR and TRAEs; Study design: RCT. Condition being studied: Lung cancer is the primary cause of cancer-related deaths, with an estimated 2.20 million new cases and 1.79 million deaths every year, and 85% of all primary lung cancers are non-small cell lung cancer. Eligibility criteria: Studies were considered eligible if they met the following criteria: (1) being an randomized
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Watson, Mark A. Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada606182.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Sage, Julien. Development of Antidepressants as Novel Agents To Treat Small Cell Lung Cancer. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada613784.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Rudin, Charles M. Genetic and Epigenetic Determinants of Lung Cancer Subtype: Adenocarcinoma to Small Cell Conversion. Defense Technical Information Center, 2015. http://dx.doi.org/10.21236/ada623599.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Nelkin, Barry D. Role of CDK5 as a Tumor Suppressor Gene in Non-Small Cell Lung Cancer. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada610950.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Yu, Guocan, Qingshan Cai, Xudong Xu, Yanqin Shen, and Kan Xu. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0034.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Yu, Guocan, Qingshan Cai, Xudong Xu, Yanqin Shen, and Kan Xu. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0034.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Li, Yong, Fang Yang, and Ya-Yong Huang. Sublobar resection versus ablation for stage I non-small-cell lung cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0075.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Peng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao, and Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.

Der volle Inhalt der Quelle
Annotation:
Review question / Objective: This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection of different regimens. Condition being studied: Immunotherapy is a relatively new treatment method for non-small cell lung cancer (NSCLC), and clinical studies confirmed that immune checkpoint inhibitors (ICIs) showed prominent efficacy in the treatment of NSCLC patients. This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Small Cell Lung Cancer" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen Bücher
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie